Heart failure, Hypertension, RNA, Cancer, Myocardial infarction, Genomics
The virus shredder: A Princeton spinout advised by a high-profile VC launches a Cas13 viral defense system
Cameron Myhrvold is one of those young scientists who’s been earning double takes for the cutting-edge research work he’s been doing, even before joining Princeton in 2020. But after getting his PhD in systems biology at Harvard seven years ago, he eventually turned to Cas13, a CRISPR ...
The virus shredder: A Princeton spinout advised by a high-profile VC launches a Cas13 viral defense system
Cameron Myhrvold is one of those young scientists who’s been earning double takes for the cutting-edge research work he’s been doing, even before joining Princeton in 2020. But after ...
We are sorry, we could not find the related article
If you are curious about Biotech and Career and Jobs
Please click on:
Subscribe to Biotech - Career and Jobs
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory?
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
Recent deals for MyoKardia and The Medicines Co. may be hard to follow, since venture investors and big pharma acquirers have largely ignored cardiovascular drugs.
Seven Biopharma Trends to Watch in 2021
It’s not all COVID-19! Check out gene editing, gene and cell therapy, and other areas.
Q1 2021: A Look at Biopharma’s Top 25 Companies by Market Cap
BioSpace takes an in-depth look at the Top 25 of Q1.
News for the month of July 2020
Find here a listing of the latest industry news in genomics, genetics, precision medicine, and beyond. Updates are provided on a monthly basis. Sign-Up for our newsletter and never miss o…